HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

490.383

-13.015-2.59%

Number of Gainers:6

Number of Losers:23

Number of Flat:4

PE:- -

High:505.901

Open:503.516

Low:489.571

Close:503.398

Volume:82.72M

Turnover:2.69B

Market Cap:313.43B

Float Cap:277.25B

Loading ...

Ascletis Pharma Expects HY Loss of Rmb319.7 MLN

IMMUNOTECH-B Reports Half-Year Results with Narrowed Loss

Immunotech Biopharm FY26 H1 Net Loss Narrows 45.8% to RMB 69.87 Million

PEIJIA-B Reports 20.1% Revenue Growth in Interim Results

Peijia Medical H1 FY26 Loss Narrows 87.4% to RMB 8.99 Million; Revenue Rises 20.1% to RMB 424.5 Million

Edding Genor Group Expects Revenue of Rmb850 MLN-Rmb900 MLN for HY

Edding Genor Expects H1 Net Loss of RMB 60 Million-RMB 70 Million vs Year-Ago Profit

Jhbp Cy - Expects Revenue of Rmb850 Mln-Rmb900 Mln for Six Months Ended 30 June 2026

THOMSON REUTERS

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million

Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY

THOMSON REUTERS

Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others

THOMSON REUTERS

BIODLINK-B Posts Interim Results with Total Revenue of RMB 246 Million, CDMO Segment Surges While Proprietary Pipeline Accelerates Global Expansion

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

China's Henlius H1 Revenue Jumps on Drug Sales, License Income

Hua Medicine Grants 200,000 Share Options at HK$ 2.6 Each

Antengene-B Turns Profitable in First Half with Net Income of RMB216 Million

Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals

Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility

Antengene FY26 H1 Returns to Profit at RMB 216.35 Million; Revenue More than Doubled to RMB 513.08 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/BK1574/news?page=14"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":490.383,"timestamp":1788250091886,"preClose":503.39795,"halted":0,"volume":82724645,"delay":0,"changeRate":-0.025854,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-13.014954,"latestTime":"09-01 16:00:00","open":503.51608,"high":505.9005,"low":489.5706,"amount":2688849767,"amplitude":0.032439,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"pbRate":3.790203,"peRate":127.340212,"turnoverRate":0.003099,"increases":6,"decrements":23,"flats":3,"marketCap":313429262448,"floatMarketCap":277247178824},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":505.9005,"amplitude":0.032439,"preClose":503.39795,"low":489.5706,"pbRate":"3.790203","latestPrice":490.383,"volume":82724645,"delay":0,"open":503.51608,"prevYearClose":556.26263,"prevWeekClose":523.873,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.773,"twentyDayClose":475.248,"sixtyDayClose":459.637,"secType":"PLATE","market":"HK","turnoverRate":0.003099,"peRate":127.340212,"marketCap":313429262448,"floatMarketCap":277247178824,"timestamp":1788250091886,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":23,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:14,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661291392","title":"Ascletis Pharma Expects HY Loss of Rmb319.7 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2661291392","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661291392?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:45","pubTimestamp":1787327122,"startTime":"0","endTime":"0","summary":"BRIEF-Ascletis Pharma Expects HY Loss Of RMB319.7 MLNAug 21 (Reuters)-Ascletis Pharma Inc1672.HK:EXPECTS LOSS OF RMB319.7 MILLION FOR H1 2026, UP 263.5% YOYEXPECTED HY RESULT AS RESEARCH AND DEVELOPMENT EXPENSES INCREASED 132.7% TO RMB341.7 MILLION, OTHERSFurther company coverage:1672.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK1515","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120386450","title":"IMMUNOTECH-B Reports Half-Year Results with Narrowed Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1120386450","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120386450?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:38","pubTimestamp":1787323092,"startTime":"0","endTime":"0","summary":"IMMUNOTECH-B (06978) has released its interim financial results for the six months ended June 30, 2026, revealing a significant improvement in its bottom line.During the period, the group recorded...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661229618","title":"Immunotech Biopharm FY26 H1 Net Loss Narrows 45.8% to RMB 69.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661229618","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661229618?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:30","pubTimestamp":1787322610,"startTime":"0","endTime":"0","summary":"Immunotech Biopharm FY26 H1 net loss narrows 45.8% to RMB 69.87 millionImmunotech Biopharm reported a first-half loss attributable to owners of RMB 69.87 million, narrowing 45.9% year over year.Basic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL2vNB0f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126074349","title":"PEIJIA-B Reports 20.1% Revenue Growth in Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1126074349","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126074349?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:18","pubTimestamp":1787321897,"startTime":"0","endTime":"0","summary":"PEIJIA-B (09996) has announced its interim results for 2026, with revenue reaching RMB 425 million, representing a year-on-year increase of 20.1%. Gross profit climbed 17.13% to RMB 290 million,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1100","09996","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295247","title":"Peijia Medical H1 FY26 Loss Narrows 87.4% to RMB 8.99 Million; Revenue Rises 20.1% to RMB 424.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295247","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295247?lang=en_us&edition=fundamental","pubTime":"2026-08-21 22:08","pubTimestamp":1787321303,"startTime":"0","endTime":"0","summary":"Peijia Medical H1 FY26 loss narrows 87.4% to RMB 8.99 million; revenue rises 20.1% to RMB 424.5 millionPeijia Medical posted revenue of RMB 424.5 million, up 20.1% year over year, in the six months en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL97k65j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1100","BK1583","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729592","title":"Edding Genor Group Expects Revenue of Rmb850 MLN-Rmb900 MLN for HY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729592","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:59","pubTimestamp":1787320752,"startTime":"0","endTime":"0","summary":"BRIEF-Edding Genor Group Expects Revenue Of RMB850 MLN-RMB900 MLN For HYAug 21 (Reuters)-Edding Genor Group Holdings Ltd6998.HK:EXPECTS REVENUE OF RMB850 MILLION-RMB900 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026Further company coverage:6998.HK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","06998","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661947295","title":"Edding Genor Expects H1 Net Loss of RMB 60 Million-RMB 70 Million vs Year-Ago Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2661947295","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661947295?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:57","pubTimestamp":1787320646,"startTime":"0","endTime":"0","summary":"Edding Genor expects H1 net loss of RMB 60 million-RMB 70 million vs year-ago profitEdding Genor flagged a first-half swing to loss, citing weaker sales, higher R&D spending, and pricing pressure expe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL47Ym1v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06998","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661295943","title":"Jhbp Cy - Expects Revenue of Rmb850 Mln-Rmb900 Mln for Six Months Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661295943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661295943?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:57","pubTimestamp":1787320627,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44H1RV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1583","BK1574","06998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188138907","title":"Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1188138907","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188138907?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:22","pubTimestamp":1787314947,"startTime":"0","endTime":"0","summary":"Ascletis Pharma-B (01672) has issued a profit warning, forecasting a net loss attributable to equity shareholders of approximately RMB 319.7 million for the six months ending June 30, 2026. This...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","01477","BK1191","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661115260","title":"Ascletis Pharma Sees H1 Loss Widening to RMB 319.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661115260","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661115260?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:01","pubTimestamp":1787313666,"startTime":"0","endTime":"0","summary":"Ascletis Pharma sees H1 loss widening to RMB 319.7 millionAscletis flagged a wider loss attributable to equity shareholders of about RMB 319.7 million for the six months ended June 30, 2026.Compares w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL949XQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","01672","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260941","title":"Ascletis Pharma - Expects Loss of Rmb319.7 Mln for H1 2026, up 263.5% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260941?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["01672","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260157","title":"Ascletis Pharma - Expected Hy Result as R&D Expenses Increased 132.7% to Rmb341.7 Mln, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260157","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260157?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313633,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0HV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1515","01672","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191189592","title":"BIODLINK-B Posts Interim Results with Total Revenue of RMB 246 Million, CDMO Segment Surges While Proprietary Pipeline Accelerates Global Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1191189592","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191189592?lang=en_us&edition=fundamental","pubTime":"2026-08-21 20:00","pubTimestamp":1787313625,"startTime":"0","endTime":"0","summary":"BIODLINK-B (01875) has announced its interim results for the six months ended June 30, 2026, revealing robust growth across its contract development and manufacturing organization (CDMO) segment...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK4139","BK1161","01875","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260315","title":"TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260315","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260315?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:47","pubTimestamp":1787312862,"startTime":"0","endTime":"0","summary":"TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionTOT BioPharm posted a net loss of RMB 59 million for the six months ended June 30, swinging from profit.Re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4m4SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B0JY6N72.USD","LU0359202008.SGD","LU0039217434.USD","LU0588546209.SGD","LU1242518931.SGD","LU0856984785.SGD","BK1161","LU0140636845.USD","LU0823426480.USD","LU0417516902.SGD","BK1576","KURE","BK1589","LU0128526141.USD","01875","LU1688375341.USD","LU1242518857.USD","LU0307460666.USD","LU0326950275.SGD","LU3063872942.SGD","LU0043850808.USD","LU0359201612.USD","LU0979878070.USD","LU0051755006.USD","LU0181495838.USD","LU0516423174.USD","LU0320764599.SGD","BK1521","LU1720050803.USD","LU1794554557.SGD","LU0327786744.USD","02269","LU0348825331.USD","LU0456846285.SGD","BK1574","LU0348735423.USD","LU0029874061.USD","LU0516423091.SGD","LU0516422366.SGD","LU0572944931.SGD","LU0417516738.SGD","LU0819121731.USD","LU0516422440.USD","SG9999002463.SGD","LU1880383366.USD","SG9999002562.SGD","LU0052750758.USD","LU0456827905.SGD","LU0516422952.EUR","LU0823426308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661267758","title":"China's Henlius H1 Revenue Jumps on Drug Sales, License Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2661267758","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661267758?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:36","pubTimestamp":1787312209,"startTime":"0","endTime":"0","summary":"China's Henlius H1 revenue jumps on drug sales, license incomeOverviewChina biopharma firm's interim revenue rose 27% yr/yr, driven by drug sales and licensingCompany expanded global footprint with ne","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0BX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","HK0000320264.USD","BK1161","HK0000165453.HKD","HK0000320223.HKD","BK1230","HK0000306701.USD","HK0000306685.HKD","06996","BK1191","06855","00656","BK1583","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661267732","title":"Hua Medicine Grants 200,000 Share Options at HK$ 2.6 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2661267732","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661267732?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:36","pubTimestamp":1787312167,"startTime":"0","endTime":"0","summary":"Hua Medicine grants 200,000 share options at HK$ 2.6 eachHua Medicine granted 200,000 share options to an employee under its share option scheme on Aug. 21, 2026.Exercise price set at HK$ 2.6 per shar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL8zj6Md:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1191","02552"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122991385","title":"Antengene-B Turns Profitable in First Half with Net Income of RMB216 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1122991385","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122991385?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:46","pubTimestamp":1787309190,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) has reported a strong turnaround in its interim results for the six months ended June 30, 2026, achieving a net profit of RMB216 million compared to a loss in the prior year...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1191","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264711","title":"Biotech Firm Antengene's H1 Revenue Jumps on Licensing Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264711","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264711?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:38","pubTimestamp":1787308735,"startTime":"0","endTime":"0","summary":"Biotech firm Antengene's H1 revenue jumps on licensing dealsOverviewBiotech company's H1 revenue rose sharply on licensing deals with UCB, K2 TherapeuticsCompany swung to H1 net profit from loss a yea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0AK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","06996","02137","BK1191","BK1161","BK1583","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143378344","title":"Henan Chemical Firm Commits 38 Million Yuan to Revamp Pharmaceutical Intermediate Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=1143378344","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143378344?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:31","pubTimestamp":1787308286,"startTime":"0","endTime":"0","summary":"A renovation project for a pharmaceutical intermediate production line in Henan Province has entered its second public review phase, with the developer planning a total investment of 38 million...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","159938","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661264647","title":"Antengene FY26 H1 Returns to Profit at RMB 216.35 Million; Revenue More than Doubled to RMB 513.08 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661264647","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661264647?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:27","pubTimestamp":1787308044,"startTime":"0","endTime":"0","summary":"Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 millionAntengene posted IFRS revenue of RMB 513.08 million, up RMB 459.9 million, for the six months ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL22M2ss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK1191","06996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":19,"pageCount":14,"totalSize":379,"code":"91000000","status":"200"}]}}